Product Images Gemtesa

The given text appears to be a table of LS Mean (SE) Change from Baseline for treatment and placebo with GEMTESA 75 mg. The table shows the change in values at week 2, 4, 8, and 12 from the baseline. The values are present for both the treatment and placebo groups. This data could be useful for researchers and analysts who are studying the effects of GEMTESA 75 mg on the patients.*

The text seems to be a table showing the LS means (with SE) change from baseline for a treatment and placebo group over 12 weeks. The treatment used is GEMTESA at a dosage of 75mg with 403 participants and a placebo group had 405 participants. The values seem to range from -2.254 to 0.50.*

This is a description for a medicine called GEMTESA. The product comes in the form of tablets and the package contains 30 tablets with the NDC code 73336-075-30. The medication is only available with a prescription. Each tablet contains 75mg of the active ingredient vibegron. The recommended dosage is one tablet per day, which can be taken whole or crushed. The full prescribing information should be read before use. The package is child-resistant and should be kept out of the reach of children. The medicine should be stored at a temperature between 20°C and 25°C. Urovant Sciences, Inc. manufactures Gemtesa, and patient resources can be found by visiting gemtesa.com or calling 1-833-UROVANT.*